Laura Morrison

724 total citations
52 papers, 465 citations indexed

About

Laura Morrison is a scholar working on Pulmonary and Respiratory Medicine, Psychiatry and Mental health and Cancer Research. According to data from OpenAlex, Laura Morrison has authored 52 papers receiving a total of 465 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pulmonary and Respiratory Medicine, 13 papers in Psychiatry and Mental health and 10 papers in Cancer Research. Recurrent topics in Laura Morrison's work include Schizophrenia research and treatment (10 papers), Cancer Genomics and Diagnostics (8 papers) and Mental Health Treatment and Access (8 papers). Laura Morrison is often cited by papers focused on Schizophrenia research and treatment (10 papers), Cancer Genomics and Diagnostics (8 papers) and Mental Health Treatment and Access (8 papers). Laura Morrison collaborates with scholars based in United States, Canada and Netherlands. Laura Morrison's co-authors include Patrick Lefèbvre, Peter L. Rady, Stephen K. Tyring, Dominic Pilon, Marie‐Hélène Lafeuille, Bruno Émond, Kruti Joshi, Maryia Zhdanava, Tejas Patel and S K Tyring and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Laura Morrison

48 papers receiving 450 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Laura Morrison United States	13	112	91	65	53	52	52	465
Steven Wang United States	12	154 1.4×	28 0.3×	58 0.9×	77 1.5×	11 0.2×	23	555
Gary Blick United States	17	68 0.6×	87 1.0×	106 1.6×	187 3.5×	6 0.1×	36	732
Sabrina Müller Germany	15	23 0.2×	64 0.7×	15 0.2×	184 3.5×	39 0.8×	48	666
Cathryn Sibbald Canada	16	45 0.4×	101 1.1×	40 0.6×	46 0.9×	8 0.2×	71	759
Joseph P. Alukal United States	13	74 0.7×	10 0.1×	165 2.5×	175 3.3×	26 0.5×	41	846
Helena M. VonVille United States	15	32 0.3×	127 1.4×	83 1.3×	101 1.9×	36 0.7×	27	642
Zhan Zhang China	10	16 0.1×	98 1.1×	39 0.6×	151 2.8×	23 0.4×	26	485
Veronica De Giorgis Italy	10	15 0.1×	36 0.4×	18 0.3×	161 3.0×	23 0.4×	22	472
Jennifer E. Gerber United States	10	14 0.1×	127 1.4×	113 1.7×	77 1.5×	24 0.5×	19	560
Daniela Giordano Italy	16	141 1.3×	47 0.5×	59 0.9×	179 3.4×	20 0.4×	38	832

Countries citing papers authored by Laura Morrison

Since Specialization

Citations

This map shows the geographic impact of Laura Morrison's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laura Morrison with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laura Morrison more than expected).

Fields of papers citing papers by Laura Morrison

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laura Morrison. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laura Morrison. The network helps show where Laura Morrison may publish in the future.

Co-authorship network of co-authors of Laura Morrison

This figure shows the co-authorship network connecting the top 25 collaborators of Laura Morrison. A scholar is included among the top collaborators of Laura Morrison based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laura Morrison. Laura Morrison is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kaye, Deborah R., Erik Muser, Laura Morrison, et al.. (2024). Characterizing the real-world economic burden of metastatic castration-sensitive prostate cancer in the United States. Journal of Medical Economics. 27(1). 381–391. 2 indexed citations

Bestvina, Christine M., Laura Morrison, Bruno Émond, et al.. (2024). Cost of genetic testing, delayed care, and suboptimal treatment associated with polymerase chain reaction versus next-generation sequencing biomarker testing for genomic alterations in metastatic non-small cell lung cancer. Journal of Medical Economics. 27(1). 292–303. 5 indexed citations

Walsh, Jessica A., Ruizhi Zhao, Natalie J. Shiff, et al.. (2024). Comparison of Real-World On-Label Treatment Persistence in Patients with Psoriatic Arthritis Receiving Guselkumab Versus Subcutaneous Tumor Necrosis Factor Inhibitors. Drugs - Real World Outcomes. 11(3). 487–499. 3 indexed citations

Bilen, Mehmet Asım, Carmine Rossi, Laura Morrison, et al.. (2024). Treatment patterns for patients with BRCA1/2-positive metastatic castration-resistant prostate cancer. The Oncologist. 30(1). 2 indexed citations

Kaye, Deborah R., Erik Muser, Laura Morrison, et al.. (2024). Real-world economic burden of metastatic castration-resistant prostate cancer before and after first-line therapy initiation. Journal of Medical Economics. 27(1). 201–214. 2 indexed citations

Gaylis, Franklin, Bruno Émond, Ameur M. Manceur, et al.. (2024). Adherence to First-Line Intravesical Bacillus Calmette-Guérin Therapy in the Context of Guideline Recommendations for US Patients With High-Risk Non-muscle Invasive Bladder Cancer. Journal of health economics and outcomes research. 109–117. 3 indexed citations

Bilen, Mehmet Asım, Carmine Rossi, Erik Muser, et al.. (2024). Homologous Recombination Repair Testing Patterns and Outcomes in mCRPC by Alteration Status and Race. ClinicoEconomics and Outcomes Research. Volume 16. 657–674. 1 indexed citations

Kaye, Deborah R., Erik Muser, Laura Morrison, et al.. (2024). Real-world economic burden associated with disease progression from metastatic castration-sensitive to castration-resistant prostate cancer on treatment in the United States. Journal of Managed Care & Specialty Pharmacy. 30(7). 684–697. 2 indexed citations

Lu, Xiaoxiao, Bruno Émond, Laura Morrison, et al.. (2023). Real-World Comparison of First-Line Treatment Adherence Between Single-Agent Ibrutinib and Acalabrutinib in Patients with Chronic Lymphocytic Leukemia. Patient Preference and Adherence. Volume 17. 2073–2084. 3 indexed citations

10.

Jacobs, Ryan, Xiaoxiao Lu, Bruno Émond, et al.. (2023). Time to Next Treatment in Patients with Chronic Lymphocytic Leukemia Initiating First-Line Ibrutinib or Acalabrutinib. Future Oncology. 20(1). 39–53. 2 indexed citations

11.

Correll, Christoph U., Carmela Benson, Bruno Émond, et al.. (2023). Comparison of clinical outcomes in patients with schizophrenia following different long-acting injectable event-driven initiation strategies. Schizophrenia. 9(1). 9–9. 11 indexed citations

12.

Sheffield, Brandon S., Bruno Émond, Marie‐Hélène Lafeuille, et al.. (2023). Cost Savings of Expedited Care with Upfront Next-Generation Sequencing Testing versus Single-Gene Testing among Patients with Metastatic Non-Small Cell Lung Cancer Based on Current Canadian Practices. Current Oncology. 30(2). 2348–2365. 24 indexed citations

13.

Émond, Bruno, et al.. (2022). Total cost of testing for genomic alterations associated with next-generation sequencing versus polymerase chain reaction testing strategies among patients with metastatic non-small cell lung cancer. Journal of Medical Economics. 25(1). 457–468. 28 indexed citations

14.

Zhdanava, Maryia, Dominic Pilon, Kruti Joshi, et al.. (2022). Excess healthcare resource utilization and healthcare costs among privately and publicly insured patients with major depressive disorder and acute suicidal ideation or behavior in the United States. Journal of Affective Disorders. 311. 303–310. 5 indexed citations

15.

Pilon, Dominic, Timothy Fitzgerald, Maryia Zhdanava, et al.. (2022). Risk of Treatment Discontinuation among Patients with Psoriasis Initiated on Ustekinumab and Other Biologics in the USA. Dermatology and Therapy. 12(4). 971–987. 4 indexed citations

16.

Zhdanava, Maryia, Dee Lin, Marie‐Hélène Lafeuille, et al.. (2021). Antipsychotic Adherence, Resource Use, and Costs Before and After the Initiation of Once-monthly Paliperidone Palmitate Therapy Among Medicaid Beneficiaries With Prior Schizophrenia Relapse. Clinical Therapeutics. 43(3). 535–548. 10 indexed citations

17.

Zhdanava, Maryia, Kruti Joshi, Ella Daly, et al.. (2020). Economic Burden of Treatment-Resistant Depression in Privately Insured U.S. Patients with Physical Conditions. Journal of Managed Care & Specialty Pharmacy. 26(8). 996–1007. 18 indexed citations

18.

Pilon, Dominic, et al.. (2020). Use of home health and other healthcare delivery pathways among privately insured patients with and without treatment-resistant depression. Current Medical Research and Opinion. 36(5). 865–874. 1 indexed citations

19.

Pilon, Dominic, John J. Sheehan, Laura Morrison, et al.. (2019). Is clinician impression of depression symptom severity associated with incremental economic burden in privately insured US patients with treatment resistant depression?. Journal of Affective Disorders. 255. 50–59. 14 indexed citations

20.

Anderton, A., et al.. (1993). A comparative study of the numbers of bacteria present in enteral feeds prepared and administered in hospital and the home. Journal of Hospital Infection. 23(1). 43–49. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact